Start the conversation
Botox manufacturer Allergan Inc. (NYSE: AGN) rejected a massive bid from pharmaceutical company Actavis Plc. (NYSE: ACT), according to The Wall Street Journal. The report says that Allergan is poised to announce its acquisition of Salix Pharmaceuticals Ltd. (Nasdaq: SLXP), which could cost nearly $10 billion. Allergan has been aggressively attempting to avoid a $53 billion hostile takeover from its rival Valeant Pharmaceuticals International Inc. (NYSE: VRX). Shares of Salix were up more than 9% in pre-market hours.